Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh

Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh

Bavarian Nordic Research Institute Gmbh

Gsf-Forschungszentrum Fur Unwelt Und Gesundheit Gmbh

Gfs Forschungszentrum Fur Umwelt Und Gesundheit Gmbh

Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh

Gsf Gesellschaft Fur Strahlen-Und Umweltforschung

Volker Erfle

Gerd Sutter

Marion Ohlmann

Stefan Wintersperger

Robert Baier

Caroline Staib

Sigried Kiesling

Ruth Brack-Werner

Markus Neumann

Horst Wolff

Simone Hornemann

Mary Jane Cardosa

Werner Mellert

Torben Saermark

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

Recombinant MVA virus and the use thereof

Recombinant MVA virus

The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.

Modified vaccinia virus Ankara (MVA) mutant and use thereof

Recombinant MVA virus, and the use thereof

The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.

Reporter gene construct for the detection of HIV Rev and HIV Tat

A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.

Vector for integration of heterologous sequences into poxviral genomes

The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.

Vaccinia virus MVA-E3L-knockout-mutants and use thereof

Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.

Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines

The present invention provides a DNA vector comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. The present invention relates also, inter alia, to recombinant poxvirses carrying heterologous coding sequences transferred by the vector according to the present invention.

A method and composition are described for the treatment of mammalian HIV infections including administering an effective subtoxic dosage of melittin (Seq. ID NO:1) to the mammal whereby the growth of HIV infected cells or the replication of the virus in the infected cells of the mammal is inhibited.

Growing community of inventors

Munich, Germany

Volker Erfle